IP Library › Granted Patent US 8,377,688
Granted Patent B2
US 8,377,688 · App. 12/871,017 · Granted Feb 19, 2013

Use of MVA to treat prostate cancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,688
App. No.
12/871,017
Granted
Feb 19, 2013
Kind
B2
Abstract

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Claims (29)

1. A recombinant modified vaccinia virus Ankara (MVA) expressing a polypeptide comprising a human prostatic acid phosphatase (PAP) antigen, wherein the recombinant MVA virus induces B-cell and T-cell immune responses against the human PAP antigen when administered to a human host.

2. The recombinant MVA virus of claim 1 , wherein the MVA virus comprises SEQ ID NO:2.

3. The recombinant MVA virus of claim 1 , wherein the MVA is MVA-Bavarian Nordic (MVA-BN).

4. The recombinant MVA virus of claim 2 , wherein the MVA is MVA-BN.

5. The recombinant MVA virus of claim 1 , wherein the recombinant MVA virus further expresses a polypeptide comprising a human prostate-specific antigen (PSA) antigen.

6. The recombinant MVA virus of claim 2 , wherein the recombinant MVA virus further expresses a polypeptide comprising a human PSA antigen.

7. The recombinant MVA virus of claim 3 , wherein the recombinant MVA virus further expresses a polypeptide comprising a human PSA antigen.

8. The recombinant MVA virus of claim 4 , wherein the recombinant MVA virus further expresses a polypeptide comprising a human PSA antigen.

9. The recombinant MVA virus of claim 5 , wherein the recombinant MVA virus further expresses the nucleotide sequence of SEQ ID NO:1.

10. The recombinant MVA virus of claim 6 , wherein the MVA virus comprises the nucleotide sequence of SEQ ID NO:1.

11. The recombinant MVA virus of claim 7 , wherein the MVA virus comprises the nucleotide sequence of SEQ ID NO:1.

12. The recombinant MVA virus of claim 8 , wherein the MVA virus comprises the nucleotide sequence of SEQ ID NO:1.

13. An immunogenic composition comprising the recombinant MVA virus of claim 1 .

14. An immunogenic composition comprising the recombinant MVA virus of claim 2 .

15. An immunogenic composition comprising the recombinant MVA virus of claim 3 .

16. An immunogenic composition comprising the recombinant MVA virus of claim 4 .

17. An immunogenic composition comprising the recombinant MVA virus of claim 5 .

18. An immunogenic composition comprising the recombinant MVA virus of claim 6 .

19. An immunogenic composition comprising the recombinant MVA virus of claim 7 .

20. An immunogenic composition comprising the recombinant MVA virus of claim 8 .

21. A kit for an immunogenic composition of human prostate cancer comprising:

(a) the recombinant MVA of claim 5 ; and

(b) instructions to administer the recombinant MVA prior to the detection of prostate cancer.

22. A kit for the treatment of human prostate cancer comprising:

(a) the recombinant MVA of claim 5 ; and

(b) instructions to administer the recombinant MVA to a human prostate cancer patient.

23. A kit for treating a human cancer patient comprising:

(a) the recombinant MVA of claim 5 ; and

(b) instructions to administer the recombinant MVA prior to, at the same time as, or after treatment with a tumoricidal dose of a taxane.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2016
From: BAVARIAN NORDIC INC.
To: BAVARIAN NORDIC A/S
Reel/Frame 037601/0048 →
CHANGE OF NAME Recorded Aug 7, 2013
From: BN IMMUNOTHERAPEUTICS, INC.
To: BAVARIAN NORDIC, INC.
Reel/Frame 030965/0065 →